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Zygomatic Metastasis From
Breast Cancer
Matteo Brucoli, MD, Francesco Arcuri, MD,
Livia Stellin, MD, Arnaldo Benech, MD, DDS
Abstract: Breast cancer continues to be the second most com-
mon cancer among women, after nonmelanoma skin cancer; in the
United States, there is an average lifetime risk of 11% for devel-
oping a breast malignancy. Metastatic tumors from distant primary
foci to the maxillofacial (MF) region are reported to account for
only 1% of all MF malignancies, usually with grave prognosis. In
the MF region, the bones more frequently involved in metastasis
are the mandible, maxilla, temporal bone, frontal bone, and malar
bone; the soft tissues more affected are gingiva, parotid gland,
tongue, submandibular gland, and cheek. We describe a unique case
of a solitary mass found in the body of the right zygoma, revealing
a metastasis from breast cancer. According to the literature, the
zygomatic complex is a very unusual site for metastasis; we found
only 4 cases of metastatic localization from lung, rectum, liver, and
uterine cancer. In MF region, oral and nasal cavity has been de-
scribed as atypical sites of metastasis from breast cancer; this is to
our knowledge the first recorded instance of malar metastasis from
breast cancer.
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B reast cancer continues to be the second most common canceramong women, after nonmelanoma skin cancer; in the United
States, there is an average lifetime risk of 11% for developing a
breast malignancy.1 An average woman has a 3% to 4% chance of
death from a breast malignancy; risk factors include family/personal
history of breast malignancy, early menarche, increasing age, late
menopause, alcohol consumption, nulliparity, and previous exposure
to ionizing radiation.2 Genetic mutations such as BRCA1/BRCA2
are positive predictors,3 and risk of disease in these individuals has
been estimated at 60% to 80%.4 Metastatic tumors from distant
primary foci to the maxillofacial (MF) region are reported to account
for only 1% of all MFmalignancies, usually with grave prognosis.5Y9
Most patients have had a previously known primary cancer; never-
theless, metastasis in MF region was the initial manifestation in ap-
proximately one third of the patients, and in some cases, the primary
tumor remains unknown despite additional investigations.10Y14 Shen
et al15 in 2009 reported a review of the Chinese and English literature
for metastatic tumors to the MF region; in the search conducted from
January 1950 to April 2007, they collected 461 articles with 746
histopathologically confirmed cases of MF metastatic tumors. Ac-
cording to their study, the most frequent sites of primary cancers
were lung and bronchus, breast, kidney, liver with internal biliary
ducts, and prostate.
In the MF region, the bones more frequently involved in
metastasis were mandible, maxilla, temporal bone, frontal bone, and
malar bone; the soft tissues more affected were gingiva, parotid
gland, tongue, submandibular gland, and cheek. We describe a
unique case of a solitary mass found in the body of the right zygoma,
revealing a metastasis from breast cancer.
CLINICAL REPORT
We introduce a case of a 61-year-old woman who underwent in
2006 a left-sided radical mastectomy with axillary clearance; the
histopathologic examination showed invasive ductal carcinoma of
the breast G3 pT4 N1a (2N+/26) with local vascular and neuronal
invasion and the following immunohistochemical profile: ER,
70%; PgR, 0%; C-erb2 positive.
The patient was put on adjuvant chemotherapy with FEC (fluo-
rouracil, epirubicin, and cyclophosphamide)Ydocetaxel (Taxotere)
from June 2006 to October 2006; from November 2006, she was put
on hormonotherapy with anastrozole with a result clinically and
radiologically free from disease until December 2009.
Laboratory tests, performed in this period as follow-up, revealed
an abnormal increase in creatine, aspartate aminotransferase, alanine
aminotransferase, and gamma-glutamyl transpeptidase levels asso-
ciated to pathologic serum levels of the tumoral markers carcino-
embryonic antigen (5.05) and CA-15-3 (70.10).
On January 2010, a positron emission tomography (PET)
total body was undertaken, and it revealed 3 foci localized in the
right iliac crest, liver, and zygoma; a computed tomography (CT)
FIGURE 1. Coronal CT scan demonstrating the right
zygomatic lesion, extended to the orbit, the maxillary sinus,
and the soft tissue of the cheek.
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showed the lesion on the right zygoma extended to the orbit, the
maxillary sinus, and the soft tissue of the cheek (Figs. 1Y5).
On February, the patient was put on hormonotherapy with
exemestane, and on March, she was referred by her general prac-
titioner to our clinic for a swelling and painful facial mass; the
medical examination revealed an asymmetry of the midface due to
the zygomatic mass and a mild proptosis; after few days, we per-
formed an incisional biopsy under general anesthesia through an
intraoral access with a high index of suspicion for breast metastasis,
and the definitive histopathologic examination confirmed our
initial diagnosis.
DISCUSSION
Immunohistochemical analysis is a reliable diagnostic tool for
identification of the likely site of the primary lesion in cases in
which unexpected metastatic foci are identified.16 Breast carcinoma
has a relatively characteristic immunohistochemical profile that
FIGURE 2. Positron emission tomography total body.
FIGURE 3. Axial CT-PET scan confirming the zygomatic
metastasis.
FIGURE 4. Axial CT-PET scan demonstrating the
hepatic mass.
FIGURE 5. Axial CT-PET scan revealing a metastasis to the
iliac crest.
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allows identification with a very high degree of certainty. Cytoker-
atins 7 and 20 allow localization of the site of origin of the metastatic
tumor cells to limited anatomic regions.17 Cytokeratin 20 is a type I
keratin that exhibits a relatively restricted range of tissue expres-
sion; it is found primarily in epithelium that derives from the gas-
trointestinal tract, urothelium, and Merkel cells of the skin.
Cytokeratin 7 is a type II keratin and is identified in a variety of
glandular epithelia to include endometrium, ovary, lung, and breast;
it seems absent for the most part in adenocarcinomas arising in the
gastrointestinal tract. Breast carcinomas typically show a cytokeratin
7Ypositive/cytokeratin 20Ynegative immune profile, as was evident
in this case.18 In addition, because the epithelial cells of the normal
breast mammary glands are responsive to estrogen and progesterone
hormone levels, the cells of adenocarcinomas arising from the breast
glands often have estrogen and progesterone receptor sites on their
cell membranes that can be decorated with appropriate immuno-
histochemical stains.19 In the present case, estrogen receptor was
positive, and progesterone receptor was negative; in conjunction
with the cytokeratin 7/20 profile, identification of the lesion as a
metastatic breast adenocarcinoma was virtually ensured. Solomayer
et al20 in 2000 published a retrospective study of 648 patients with
metastatic breast cancer treated from 1977 to 1985. First metastasis
was seen in the skeletal system (thoracic spine, pelvis, lumbar spine,
and ribs) in 296 patients (46%), in the visceral organs (liver, lung,
brain, and ovaries) in 268 patients (41%), and in both systems in
84 patients (13%). The disease remained confined to the skeleton or
the visceral system in 180 patients (28%) and 188 patients (29%),
respectively. Two hundred eighty patients (43%) developed both
bone and visceral metastases. According to other studies,21,22
patients with bone metastases at the time of first relapse had a sig-
nificantly better prognosis in terms of survival, overall survival, and
metastasis-free interval than patients with visceral metastases.
Patients with both osseous and visceral metastases had the same
prognosis as patients with visceral metastases only at first relapse.
In conclusion, the above case is significant for multiple reasons;
according to the literature, the zygomatic complex is a very unusual
site for metastasis; we found only 4 cases of metastatic localization
from lung,23 rectum,24 liver,25 and uterine26 cancer. In MF region,
oral27 and nasal28 cavities have been described as atypical sites of
metastasis from breast cancer; this is to our knowledge the first
recorded instance of malar metastasis from breast cancer.
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Huge Maxillofacial Teratomas
Bo Li, PhD,*Þ Xing Long, PhD, DDS,Þ Zhongxing Wu, PhD,Þ
Xinming Chen, PhDþ
Abstract: Teratomas arising from the head and neck are extremely
rare. Sporadic reports in the literature mostly involve infant and
young people. In this clinical report, we present a huge teratoma of
the infratemporal fossa in an old patient. Current diagnosis and man-
agement approaches of this rare entity are described.
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